Compare DFLI & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | NXTC |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | 141 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1M | 24.4M |
| IPO Year | N/A | 2019 |
| Metric | DFLI | NXTC |
|---|---|---|
| Price | $1.52 | $5.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.25 | ★ $23.00 |
| AVG Volume (30 Days) | 297.5K | ★ 3.0M |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $1.55 |
| 52 Week High | $5.15 | $15.74 |
| Indicator | DFLI | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.